Skip to main content
SpringerLink
Log in

The Role of Colony-Stimulating Factors in the Treatment of Acute Leukaemia

  • Review Article
  • Biopharmaceuticals
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

The currently available haemopoietic growth factors granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used in the treatment of acute leukaemia with 2 objectives: (i) to reduce the time to neutrophil recovery after intensive chemotherapy and/or haemopoietic progenitor transplantation; and (ii) in acute myeloid leukaemia, to recruit leukaemic cells into the cell cycle in order to increase the number of blasts susceptible to cycle-specific cytotoxic drugs.

In acute lymphoblastic leukaemia, the use of G-CSF or GM-CSF shortens the duration of neutropenia, and may facilitate adherence to the chemotherapy schedule. However, only 1 study has demonstrated an increase in the complete remission rate, and this was in only 1 subgroup of patients (>60 years old).

In acute myeloid leukaemia, the administration of G-CSF or GM-CSF after chemotherapy is well tolerated and is not associated with a stimulation of the leukaemic clone. In 4 out of 5 large randomised placebo-controlled studies, use of colony-stimulating factors led to a reduction of the duration of neutropenia. The complete remission rate was significantly higher for patients receiving growth factors in 2 studies, 1 with G-CSF and 1 with GM-CSF. However, only 1 of these studies, that with GM-CSF, demonstrated improved patient survival.

The effect of G-CSF or GM-CSF given before and/or during chemotherapy of acute myeloid leukaemia has been evaluated in 4 randomised studies. The results are currently not sufficient to recommend the use of either growth factor in this indication.

Many questions remain regarding the optimal dosage and schedule of administration of G-CSF or GM-CSF in acute leukaemia. The reduction of time to neutrophil recovery observed when the growth factor is administered after chemotherapy is not always translated into a benefit for the patient. Careful clinical and cost-effectiveness studies are necessary before routinely using these factors in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Estey E. Use of colony-stimulating factors in the treatment of acute myeloid leukaemia. Blood 1994; 83: 2015–9.

    PubMed  CAS  Google Scholar 

  2. Touw I, Groot-Loonen J, Broeders L, et al. Recombinant hematopoietic growth factors fail to induce a proliferative response in precursor B acute lymphoblastic leukaemia. Leukaemia 1989; 3: 356–63.

    CAS  Google Scholar 

  3. Makrynikola V, Kabral A, Bradstock K.F. Effects of recombi nant human cytokines in precursor-B acute lymphoblastic leukaemia cells. Exp Hematol 1991; 19: 674–9.

    PubMed  CAS  Google Scholar 

  4. Ode DL, Zhou M, Findley HW, et al. The effect of recombinant GM-CSF and G-CSF on the bone marrow cells of children with acute lymphoblastic leukaemia. Leukaemia 1992; 6: 1210–2.

    CAS  Google Scholar 

  5. Tomeczkowski J, Yarisan E, Wieland B, et al. Absence of GCSF receptors and absent response to G-CSF in childhoood Burkitt’s lymphoma and B-ALL cells. Br J Haematol 1995; 89: 771–9.

    Article  PubMed  CAS  Google Scholar 

  6. Freedman MH, Grunberger T, Correa P, et al. Autocrine and paracrine growth control by granulocyte-monocyte colonystimulating factor of acute lymphoblastic leukaemia cells. Blood 1993; 81: 3068–75.

    PubMed  CAS  Google Scholar 

  7. Mirro J, Hurwitz CA, Behm FG, et al. Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukaemia. Leukaemia 1993; 7: 1026–33.

    Google Scholar 

  8. Kita K, Nishii K, Ohishi K, et al. Frequent gene expression of granulocyte colony-stimulating factor (G-CSF) receptor in CD7+ surface CD3- acute lymphoblastic leukaemia. Leukaemia 1993; 7: 1184–90.

    CAS  Google Scholar 

  9. Tsuchiya H, Adachi N, Asou N, et al. Responses to granulocyte colony stimulating factor (G-CSF) and granulocyte-macro-phage CSF in Phi-positive acute lymphoblastic leukaemia with myeloid surface markers. Blood 1991; 77: 411–3.

    PubMed  CAS  Google Scholar 

  10. Komada Y, Zhou YW, Zhang SL, et al. Role in growth regulation of cytokines and cytokine receptors in acute lymphoblastic leukaemia expressing myeloid markers. Br J Haematol 1992; 84: 408–15.

    Article  Google Scholar 

  11. Shimoda K, Okamura S, Harada N, et al. Granulocyte colonystimulating factor receptors on human acute leukaemia: biphenotype leukemic cells possess granulocyte colony-stimulating factor receptors. Cancer Res 1992; 52: 3052–5.

    PubMed  CAS  Google Scholar 

  12. Tsao CJ, Cheng TY, Chang SL, et al. Effects of granulocytemacrophage colony stimulating factor and interleukin-6 on the growth of leukemic blasts in suspension culture. Int J Cell Cloning 1992; 10: 166–72.

    Article  PubMed  CAS  Google Scholar 

  13. Brandt SJ, Peters WP, Arwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–76.

    Article  PubMed  CAS  Google Scholar 

  14. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombi nant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–6.

    PubMed  CAS  Google Scholar 

  15. Blazar BR, Kersey JH, McGlave PB, et al. In vivo administration of recombinant human granulocyte-macrophage colonystimulating factor in acute lymphoblastic leukaemia patients receiving purged autografts. Blood 1989; 73: 849–57.

    PubMed  CAS  Google Scholar 

  16. Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–20.

    Article  PubMed  CAS  Google Scholar 

  17. Nemunaitis J, Buckner CD, Appelbaum FR. Phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77: 2065–71.

    PubMed  CAS  Google Scholar 

  18. Carlo-Stella C, Mangoni L, Almici C, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted dose mafosfamide-purged autologous marrow. Blood 1992; 80: 2412–8.

    PubMed  CAS  Google Scholar 

  19. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–8.

    Article  PubMed  CAS  Google Scholar 

  20. De Witte T, Gratwohl A, Van der Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359–65.

    PubMed  Google Scholar 

  21. Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukaemia or malignant lymphoma. Blood 1992; 80: 2188–95.

    PubMed  CAS  Google Scholar 

  22. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. A phase III randomized placebo controlled study of lenograstim (glycosylated rHuG-CSF) in pediatrie and adult autologous or allogeneic bone marrow transplantation. Lancet 1994; 843: 696–700.

    Article  Google Scholar 

  23. Rabinowe SN, Neuberg D, Bierman PJ, et al. Long term fol low-up of a Phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81: 1903–08.

    PubMed  CAS  Google Scholar 

  24. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukaemia. N Engl J Med 1990; 523: 871–7.

    Article  Google Scholar 

  25. Kantarjian H, Estey E, O’Brien S, et al. Intensive chemotherapy with mitoxantrone and high dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of acute lymphocytic leukaemia. Blood 1992; 79: 876–81.

    PubMed  CAS  Google Scholar 

  26. Ohno R, Tomonaga M, Ohshima T, et al. A randomized control led study of granulocyte colony-stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukaemia. Int J Hematol 1993; 58: 73–81.

    PubMed  CAS  Google Scholar 

  27. Larson RA, Linker CA, Dodge RK, et al. Granulocyte colony- stimulating factor (filgrastim) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukaemias receiving intensive remission induction chemotherapy: Cancer and Leukaemia Group B study 911 [abstract 9951. Proc Am Soc Clin Oncol 1994; 13: 305.

    Google Scholar 

  28. Ottman OG, Hoelzer D, Gracien E, et al. Concomitant granulo cyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukaemia. Blood 1995; 86: 444–50.

    Google Scholar 

  29. Weiss M, Berman E, Maslak P, et al. Rapid remission induction therapy in adult acute lymphoblastic leukaemia without vincristine or prednisone [abstract 212). Blood 1993; I Suppl.: 56a.

    Google Scholar 

  30. Ifrah N, Harousseau JL, Jouet JB, et al. Evaluation of an inten sive and brief treatment including early ABMT and support by rGM-CSF in adult ALL: a GOELAMS study. Proc EBMT Annu Meet. In press.

  31. Weite K, Reiter A, Mempel K, et al. A randomized Phase III study of the efficacy of granulocyte colony-stimulating factor in children with high risk acute lymphoblastic leukaemia. J Clin Oncol 1996; 87: 3143–50.

    Google Scholar 

  32. Lange B, Valtieri M, Santoli D, et al. Growth factor requirement of childhood acute leukaemia: establishment of GM-CSF dependent cell lines. Blood 1987; 70: 192–9.

    PubMed  CAS  Google Scholar 

  33. Vellenga E, Ostapovicz D, O’Roorke B, et al. Effects of IL3, GM-CSF and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukaemia 1987; 1: 584–9.

    CAS  Google Scholar 

  34. Griffin JD, Young D, Herrmann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukaemia. Blood 1986; 67: 1448–53.

    PubMed  CAS  Google Scholar 

  35. Asano Y, Shiboya T, Okamura S, et al. Effect of recombinant granulocyte-macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Res 1987; 47: 5647–8.

    PubMed  CAS  Google Scholar 

  36. Kelleher C, Miyauchi J, Wong G, et al. Synergism between recombinant growth factors, GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukaemia. Blood 1987; 69: 1498–503.

    PubMed  CAS  Google Scholar 

  37. Vellenga E, Young DC, Wagner K, et al. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukaemia. Blood 1987; 69: 1771–6.

    PubMed  CAS  Google Scholar 

  38. Vellenga E, Delwel R, Tuw I, et al. Patterns of acute myeloid leukemic colony growth in response to recombinant granulocyte-macrophage colony stimulating factor. Exp Hematol 1987; 15: 652–6.

    PubMed  CAS  Google Scholar 

  39. Delwel R, Salem M, Pellens C, et al. Growth regulation of hu man acute myeloid leukaemia: effects of five recombinant hematopoietic growth factors in a serum-free culture system. Blood 1988; 72: 1944–9.

    PubMed  CAS  Google Scholar 

  40. Hoang T, Nara N, Wong G, et al. Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukaemia. Blood 1988; 68: 313–6.

    Google Scholar 

  41. Lista P, Brizzi MF, Avanzi G. Induction of proliferation of my eloblastic leukaemia cells with hematopoietic growth factors. Leukaemia Res 1988; 12: 441–7.

    Article  CAS  Google Scholar 

  42. Budel LM, Touw IP, Delwel R, et al. Granulocyte colony-stim ulating factor receptors in human acute myelocytic leukaemia. Blood 1989; 74: 2668–73.

    PubMed  CAS  Google Scholar 

  43. Onetto-Pothier N, Aumont N, Haman A, et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukaemia. Blood 1990; 75: 59–66.

    PubMed  CAS  Google Scholar 

  44. Vadhan-Raj S, Keating M, Le Maistre A, et al. Effects of recom binant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545–52.

    Article  PubMed  CAS  Google Scholar 

  45. Antin K, Smith BR, Holmes W, et al. Phase I/I I study of recom binant granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705–13.

    PubMed  CAS  Google Scholar 

  46. Ganser A, Volkers B, Greher J, et al. Recombinant human GM-CSF in patients with myelodysplastic syndrome: a phase I/II trial. Blood 1989; 73: 31–7.

    PubMed  CAS  Google Scholar 

  47. Hermann F, Lindemann A, Klein H, et al. Effect of recombinant GM-CSF in patients with myelodysplastic syndrome with excess blasts. Leukaemia 1989; 3: 335–8.

    Google Scholar 

  48. Thompson JA, Lee DJ, Kid P, et al. Subcutaneous granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics and hematological effects. J Clin Oncol 1989; 7: 629–37.

    PubMed  CAS  Google Scholar 

  49. Gradishar W, Le Beau MM, O’Laughlin R, et al. Clinical and cytogenetic responses to GM-CSF in therapy related myelodysplastic syndromes. Blood 1992; 80: 2463–70.

    PubMed  CAS  Google Scholar 

  50. Willemze R, Van Der Lely N, Zwierzina H, et al. A randomized phase I/I I multicenter study of recombinant human GM-CSF therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukaemia. Ann Hematol 1992; 64: 173–80.

    Article  PubMed  CAS  Google Scholar 

  51. Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. Ann Intern Med 1992; 110: 976–84.

    Google Scholar 

  52. Negrin RS, Jagler A, Kobayashi Y, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1992; 78: 36–43.

    Google Scholar 

  53. Yoshida Y, Hirashima K, Asano S, et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78: 378–84.

    Article  PubMed  CAS  Google Scholar 

  54. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for MDS [abstract]. Blood 1993; 82 Suppl. 1: 196a.

    Google Scholar 

  55. Wong WY, Williams D, Sovak ML, et al. Terminal acute myelogenous leukaemia in a patient with congenital agranulocytosis. Am J Hematol 1993; 43: 133–8.

    Article  PubMed  CAS  Google Scholar 

  56. Weinblatt ME, Scimeca P, James-Herry A, et al. Transformation of congenital neutropenia in monosomy 7 and acute nonlymphoblastic leukaemia in a child treated with granulocyte colony-stimulating factor. J Pediatr 1995; 126: 263–5.

    Article  PubMed  CAS  Google Scholar 

  57. Imashuku S, Hibi S, Kataoka-Morimoto Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995; 89: 188–90.

    Article  PubMed  CAS  Google Scholar 

  58. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leu kaemia after treatment of aplastic anemia with G-CSF. N Engl J Med 1992; 326: 1294–5.

    Article  PubMed  CAS  Google Scholar 

  59. Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukaemia preceded by severe congenital neutropenia. N Engl J Med 1995; 333: 487–93.

    Article  PubMed  CAS  Google Scholar 

  60. Estey EH, Dixon D, Kantarjian H, et al. Treatment of poorprognosis, newly diagnosed acute myeloid leukaemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75: 1766–9.

    PubMed  CAS  Google Scholar 

  61. Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukaemia at higher age or after relapse. Blood 1991; 78: 1190–7.

    PubMed  CAS  Google Scholar 

  62. Kantarjian H, Talpaz M, Kontoyiannis D, et al. Treatment of chronic myelogenous leukaemia in accelerated and blastic phases with daunorubicine, high-dose cytarabine and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 398–405.

    PubMed  CAS  Google Scholar 

  63. Rowe JM, Andersen J, Mazza JJ, et al. A randomized placebocontrolled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern Cooperative Oncology Group. Blood 1995; 86: 457–62.

    PubMed  CAS  Google Scholar 

  64. Stone RM, Berg DT, George SL, et al. Granulocyte-macro phage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. N Engl J Med 1995; 232: 1671–7.

    Article  Google Scholar 

  65. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukaemia. N Engl J Med 1995; 232: 1678–83.

    Article  Google Scholar 

  66. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind, pla cebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukaemia: a Southwest Oncology Group Study |abstract|. Blood 1995; 86 Suppl. 1: 434a.

    Google Scholar 

  67. Heil G, Hoelzer D, Sanz MA, et al. Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de nova acute myeloid leukaemia [abstract]. Blood 1995; 86 Suppl. 1:267a.

    Google Scholar 

  68. Souza LM, Boone TC, Abrilove JL, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61–5.

    Article  PubMed  CAS  Google Scholar 

  69. Begley CG, Metcalf D, Nicola NA. Purified colony-stimulating factors (G-CSF and GM-CSF) induce differentiation in HL-60 cells with suppression of clonogenicity. Int J Cancer 1987; 39: 99–105.

    Article  PubMed  CAS  Google Scholar 

  70. Giralt S, Escudier S, Katnarjian M, et al. Preliminary results of treatment with filgrastim for relapse of leukaemia and myelodysplasia after allogenic bone marrow transplantation. N Engl J Med 1993; 329: 757–81.

    Article  PubMed  CAS  Google Scholar 

  71. Ohno R, Hiraoka A, Tanimoto M, et al. No increase of leukae mia relapse in newly diagnosed patients with acute myeloid leukaemias who received granulocyte colony-stimulating factor for life threatening infection during remission induction and consolidation therapy. Blood 1993; 81: 561–2.

    PubMed  CAS  Google Scholar 

  72. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukaemia followed by cyclespecific chemotherapy in vitro. Leukaemia 1990; 4: 826–34.

    CAS  Google Scholar 

  73. Miyauchi J, Kelleher CA, Wang C, et al. Growth factors influ ence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989; 73: 1272–8.

    PubMed  CAS  Google Scholar 

  74. Cannistra SA, Groshek P, Griffin JD. Granulocyte-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukaemia and in the myeloid blast crisis phase of chronic myeloid leukaemia. Leukaemia 1989; 3: 328–44.

    CAS  Google Scholar 

  75. Lista P, Brizzi M, Rossi M, et al. Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment. Br J Haematol 1990; 73: 21–6.

    Article  Google Scholar 

  76. Butturini A, Santucci AM, Gale RD, et al. GM-CSF incubation prior to treatment with cytarabine or doxorubicine enhances drug activity against AML cells in vitro: a model for leukaemia chemotherapy. Leuk Res 1990; 9: 743–9.

    Article  Google Scholar 

  77. Karp JE, Burke PJ, Donehower RP. Effect of rh GM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukaemia: comparability with drug-induced humoral stimulatory activity. Leukaemia 1990; 4: 553–6.

    CAS  Google Scholar 

  78. Hiddemann W, Kielhl M, Zühlsdorf M, et al. Granulocyte-mac rophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukaemia. Semin Oncol 1992; 19: Suppl. 21: 31–7.

    PubMed  CAS  Google Scholar 

  79. Yang GS, Minden MD, McCulloch EA. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukaemia 1993; 7: 1012–9.

    CAS  Google Scholar 

  80. Bhalla K, Birkhofer M, Arlin Z, et al. Effect of recombinant GM-CSF on the metabolism of cytosine-arabinoside in normal and leukemic human bone marrow cells. Leukaemia 1988; 2: 810–3.

    CAS  Google Scholar 

  81. Van Der Lely N, De Witte T, Mous P, et al. Prolonged exposure to cytosine arabinoside in the presence of haematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 1991; 19: 267–72.

    Google Scholar 

  82. Baer MR, Bernstein SH, Brunetto VL, et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukaemia. Blood 1996; 87: 1484–94.

    PubMed  CAS  Google Scholar 

  83. Koistinen P, Wang C, Curtis JE, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukaemia 1991; 5: 789–95.

    CAS  Google Scholar 

  84. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750–7.

    PubMed  CAS  Google Scholar 

  85. Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukaemia. Blood 1991; 77: 700–11.

    PubMed  CAS  Google Scholar 

  86. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly di agnosed acute myelogenous leukaemia with granulocytemacrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–55.

    PubMed  CAS  Google Scholar 

  87. Archimbaud A, Fenaux P, Reiffers J, et al. Granulocyte-macro phage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukaemia. Leukaemia 1993; 7: 372–7.

    CAS  Google Scholar 

  88. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colonystimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–8.

    PubMed  CAS  Google Scholar 

  89. Ohno R, Naoe T, Kanamaro A, et al. A double-blind, controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukaemia. Blood 1994; 73: 2086–92.

    Google Scholar 

  90. Witz F, Harousseau JL, Sadoun A, et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukaemia [abstract]. Blood 1995; 86 Suppl. 1: 512a.

    Google Scholar 

  91. Löwenberg B, Suciu S, Zittoun R, et al. GM-CSF during as well as after induction chemotherapy in elderly patients with acute myeloid leukaemia [abstract]. Blood 1995; 86 Suppl. 1: 433a.

    Google Scholar 

  92. Büchner T, Hiddemann W, Rottmann R, et al. Multiple course chemotherapy with or without GM-CSF priming and longterm administration for newly diagnosed AML [abstract 9851]. Proc Am Soc Clin Oncol 1993; 12: 301.

    Google Scholar 

  93. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukaemia: a randomized trial by the EORTC Leukaemia cooperative group. J Clin Oncol 1996; 14: 2150–9.

    PubMed  CAS  Google Scholar 

  94. Löwenberg B, Boogaerts MA, Wellenga E, et al. Various mo dalities of use of GM-CSF in the treatment of acute myelogenous leukaemia: a Hovon-SAKK randomized study [abstract]. Blood 1995; 86 Suppl. 1: 512a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, University Hospital, Nantes, France

    Jean-Luc Harousseau

Authors
  1. Jean-Luc Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harousseau, JL. The Role of Colony-Stimulating Factors in the Treatment of Acute Leukaemia. BioDrugs 7, 448–460 (1997). https://doi.org/10.2165/00063030-199707060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199707060-00004

Keywords

Search

Navigation